'Zombie' Cells Created by Transplanting Genomes Into Dead Bacteria
Researchers have revived a dead bacterial cell by transplanting the complete genome of Mycoplasma capricolum into a chemically inactivated host, creating the first living synthetic bacterium assembled from non‑living parts. The experiment builds on the 2010 landmark where a synthetic genome was inserted into a living cell, but now demonstrates that a dead chassis can be reanimated. This proof‑of‑concept expands the toolkit of synthetic biology, allowing engineered microbes to be built more rapidly. The work was reported on 23 March 2026 and is hailed as a milestone in re‑defining the boundary between life and death.
STAT+: Pfizer’s Lyme Vaccine Shows Efficacy, but Misses Key Statistical Hurdle
Pfizer and Valneva’s experimental Lyme vaccine cut the risk of infection by more than 70% in a late‑stage trial, offering a promising preventive tool for a disease that affects roughly 476,000 Americans annually. The study, however, missed its primary statistical...
STAT+: Apogee Therapeutics Data Show Long-Acting Eczema Drug Induced Relief with Less Frequent Injections
Apogee Therapeutics reported that its experimental long‑acting eczema biologic, zumilokibart, achieved sustained skin‑clearance in a mid‑stage trial. Seventy‑five percent of patients receiving the drug every three months and 85 % of those dosed every six months maintained an EASI‑75 response after...
IntraBio Reports the US FDA’s sNDA Submission of Aqneursa for Ataxia-Telangiectasia
IntraBio has filed a supplemental New Drug Application (sNDA) with the U.S. FDA seeking approval of Aqneursa (levacetylleucine) for Ataxia‑Telangiectasia (A‑T). The filing is supported by a Phase III trial that met its primary and key secondary endpoints and demonstrated a...
HUTCHMED Initiates P-III Trial of HMPL-760 + R-GemOx for R/R Diffuse Large B-Cell Lymphoma in China
HUTCHMED has launched a Phase III trial of HMPL‑760 combined with R‑GemOx in relapsed/refractory diffuse large B‑cell lymphoma (DLBCL) patients in China, dosing the first patient on March 20, 2026. The study will enroll approximately 240 patients who have failed first‑line therapy and...
ADA2 Deficiency Boosts Cell Death, Metabolic Issues
A new study reveals that deficiency of the enzyme ADA2 markedly increases programmed cell death and disrupts normal metabolic pathways. Researchers observed heightened apoptosis in immune cells and multiple organ tissues of ADA2‑knockout mice, accompanied by severe inflammation and organ...
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
Longevity investing has shifted from hype to data‑driven strategies, according to LongeVC partners Sergey Jakimov and Artem Trotsyuk. They argue that startups must focus on measurable, disease‑specific mechanisms rather than treating aging as a single target, aligning with FDA and...
A Targeted Nanozyme for STING Activation Improves BiTEs Therapy Outcomes in Colorectal Cancer
Researchers engineered a tumor‑targeted nanozyme, MnO2‑dsDNA@BiTE/APT, that simultaneously delivers a double‑strand DNA STING agonist and a PD‑L1/CD3 bispecific T‑cell engager. The MnO2 carrier releases Mn2+ ions, activating the STING pathway, while the surface‑bound BiTE recruits T cells to cancer cells....
Dizal Reports the P-III (WU-KONG28) Trial Results on Zegfrovy (Sunvozertinib) in EGFRm NSCLC
Dizal announced topline results from its Phase 3 WU‑KONG28 trial, comparing oral once‑daily Zegfrovy (sunvozertinib) to platinum‑based chemotherapy as first‑line treatment for advanced NSCLC with EGFR exon 20 insertion mutations. The study met its primary endpoint, demonstrating a statistically significant improvement in...
Mesoporous Silica Nanoparticles‐Based Formulations for Enhanced Oral Delivery of Peptide Drugs: A Case Study on Insulin
Researchers engineered mesoporous silica nanoparticles (MSN) to encapsulate insulin and co‑formulated them with succinylated β‑lactoglobulin into pH‑responsive tablets. Surface grafting with polyethylene glycol and phosphonate groups boosted insulin solubility by roughly 2.5‑fold and stabilized the particles in gastrointestinal fluids. The...
Social Status Influences T-Cell Synapse Strength
A new study in Cell Research links social hierarchy to immune competence by showing that pre‑frontal cortical synaptic strength governs peripheral T‑cell activity. Lower‑ranking animals displayed weakened synaptic transmission, which correlated with reduced T‑cell activation, while higher‑ranking peers exhibited stronger...
Powering the Next Wave of Cell Therapy: From iPSC-Derived Cells to In Vivo Reprogramming
Induced pluripotent stem cells (iPSCs) are being engineered into diverse therapeutic cell types, while in vivo reprogramming aims to convert resident cells directly within patients, eliminating traditional cell‑manufacturing steps. Both strategies depend on precise recombinant growth factors, cytokines, extracellular matrix proteins...
Reinforced Biotubes: Readily Available Regenerative Vascular Grafts
Researchers Cheng, Zhi and Midgley have unveiled reinforced biotubes—bioengineered vascular grafts that combine living cells with nanofibrous reinforcement—to address durability and availability limits of current grafts. The tubes are fabricated in bioreactors, seeded with smooth‑muscle and endothelial progenitor cells, and...
Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality
Gene‑therapy candidates for hereditary hearing loss are gaining traction as safety concerns ease with localized delivery. Regeneron’s DB‑OTO and Eli Lilly’s AK‑OTOF have each demonstrated clinically meaningful hearing improvements in early‑stage trials, positioning them as frontrunners for the first approved deafness...
9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty
The FDA’s National Priority Voucher (CNPV) program, launched in June 2025, promises to cut drug review times from 10‑12 months to just one or two months for products that meet defined national priorities. Early successes include Johnson & Johnson’s Tecvayli/Darzalex...
NADPH Oxidase-1 Suppression Prolongs the Antidepressant-Like Effect of Ketamine
Researchers introduced K‑4, a novel AMPA‑receptor positive allosteric modulator, which produced rapid and sustained antidepressant‑like effects in treatment‑resistant depression rat models. Bulk RNA‑seq revealed that K‑4 markedly down‑regulated NADPH oxidase‑1 (NOX‑1) in the medial prefrontal cortex and lateral habenula. Pharmacological...
J. Michael Bishop, Nobel Prize Winner for Cancer Research, Dies at 90
J. Michael Bishop, Nobel laureate who uncovered oncogenes, died at 90 from pneumonia. His 1989 Nobel Prize with Harold Varmus identified gene families that mutate into cancer‑causing oncogenes, fundamentally altering tumor biology. Bishop joined UCSF in 1968, later serving as...
FDA Drug Safety Communication: Revised Recommendations for Celexa (Citalopram Hydrobromide) Related to a Potential Risk of Abnormal Heart Rhythms with...
The FDA issued a Drug Safety Communication clarifying that citalopram (Celexa) should not be prescribed above 40 mg daily because higher doses significantly prolong the QT interval and can trigger fatal Torsade de Pointes. The label now mandates a maximum of...
FDA Drug Safety Communication: Updated Information About the Risk of Blood Clots in Women Taking Birth Control Pills Containing Drospirenone
The FDA has updated labels for drospirenone‑containing oral contraceptives after reviewing epidemiologic studies that suggest a potentially higher risk of venous thromboembolism compared with other progestins. The new warnings note that some studies report up to a three‑fold increase in...
FDA Drug Safety Communication: New Warning and Contraindication for Blood Pressure Medicines Containing Aliskiren (Tekturna)
The FDA issued a drug safety communication on April 20, 2012, adding a contraindication for aliskiren‑containing antihypertensives when combined with ACE inhibitors or ARBs in patients with diabetes, and a warning for those with moderate to severe renal impairment. The...
FDA Drug Safety Communication: Updated Information on Drug Interactions Between Victrelis (Boceprevir) and Certain Boosted HIV Protease Inhibitor Drugs
The FDA issued an updated Drug Safety Communication warning that co‑administration of Victrelis (boceprevir) with ritonavir‑boosted HIV protease inhibitors—atazanavir, darunavir, or lopinavir/ritonavir—is not recommended for patients co‑infected with hepatitis C and HIV. The interaction lowers blood concentrations of both drugs,...
FDA Drug Safety Communication: Safety Review Update of Cancer Drug Revlimid (Lenalidomide) and Risk of Developing New Types of Malignancies
The FDA added a safety warning to Revlimid (lenalidomide) after clinical trials showed a markedly higher incidence of second primary malignancies in newly diagnosed multiple myeloma patients. Pooled data revealed a three‑fold increase (7.9% vs 2.8%) in cancers such as...
FDA Drug Safety Communication: Cefepime and Risk of Seizure in Patients Not Receiving Dosage Adjustments for Kidney Impairment
The FDA issued a Drug Safety Communication reminding clinicians to adjust cefepime doses for patients with creatinine clearance ≤ 60 mL/min. Non‑convulsive status epilepticus has been linked to inappropriate dosing, with 59 reported cases since 1996, 58 of which involved renal dysfunction...
FDA Drug Safety Communication: Seizure Risk for Multiple Sclerosis Patients Who Take Ampyra (Dalfampridine)
The FDA issued a Drug Safety Communication warning that dalfampridine (Ampyra), approved to improve walking in multiple sclerosis patients, carries a significant seizure risk, especially shortly after therapy initiation. Post‑marketing data show most seizures occur within days‑to‑weeks and in patients...
FDA Drug Safety Communication: FDA Recommends Against Use of Revatio (Sildenafil) in Children with Pulmonary Hypertension
The FDA issued a drug safety communication recommending that Revatio (sildenafil) not be prescribed to children aged 1‑17 for pulmonary arterial hypertension. A long‑term pediatric trial of 234 patients showed no exercise benefit and a three‑fold increase in mortality at...
Competitive ELISA Explained: Mechanism, Data Interpretation, and Research Applications
Competitive ELISA is a plate‑based assay where an enzyme‑labeled antigen competes with sample antigen for a limited antibody binding site, producing an inverse signal. As target concentration rises, the measured colorimetric signal falls, generating a descending standard curve. The format...
Genetic Study Finds Links Between Height and Risk of Cardiovascular and Reproductive Conditions in East Asian People
A large‑scale GWAS of over 120,000 Han Taiwanese participants identified 293 genetic variants linked to height and five linked to familial short stature. The study found that greater genetically‑predicted height raises the risk of atrial fibrillation and endometriosis in East...
Could Ozempic Help People Whose Cancer Has Spread to the Brain?
A large retrospective analysis of over 19,000 patients with cancer, type 2 diabetes and brain metastases found that those prescribed GLP‑1 receptor agonists such as Ozempic or Wegovy experienced a 37% reduction in three‑year mortality compared with matched controls. The survival...
Lab-Grown Brain Models Reveal Unique Electrical Patterns in Different Types of Autism
Researchers created patient‑derived brain organoids from urine cells and recorded their electrical activity, revealing distinct electrophysiological signatures for neurotypical controls, syndromic autism, and idiopathic autism. Organoids from syndromic cases showed hyper‑activity, while the idiopathic sample displayed reduced firing rates. Principal...
The Deep Cave Bacteria Defying Modern Medicine
Scientists exploring the isolated Lechuguilla Cave discovered microbial communities that are resistant to virtually all natural antibiotics, despite being sealed off for millions of years. Genomic analysis of a *Paenibacillus* strain revealed dozens of known resistance genes and five entirely...
Kyoto Medical Firm to Launch Personal iPS Cell Storage Service
Kyoto-based iPS Portal Inc. will launch a personal induced pluripotent stem cell storage service in April, allowing individuals to generate iPS cells from their own blood for future clinical use. The service, developed with pharmaceutical experts, will cost between 10 million...
UK Study Reveals No Additional Advantage of Surfactant Therapy in Severe Bronchiolitis Cases in Infants
UK researchers completed the largest randomized trial evaluating exogenous surfactant in infants with severe bronchiolitis requiring mechanical ventilation. The Bronchiolitis Endotracheal Surfactant Study (BESS) enrolled 232 infants across 15 pediatric centers and found that surfactant administration did not shorten ventilation...
Psychedelic Drug MDMA Could Help Treat PTSD—But There's a Reason It's Not Widely Available
Australia became the first nation to reclassify MDMA from a prohibited to a controlled substance, permitting its use in PTSD treatment under strict conditions. The 2026 guidelines limit MDMA‑assisted psychotherapy to adults who have not responded to first‑line therapies, require...
El Plan De Ignacio Del Río Goudie Para Polinizar Estados Unidos
Chilean agritech startup Biopollen, spun off from Ignacio del Río Goudie's holding, commercializes a liquid‑pollen technology that boosts fruit set in low‑pollination crops. The method harvests fresh pollen, keeps it viable in a chilled liquid, and sprays it aerially with...
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Prothena and its partners presented new clinical data on prasinezumab for Parkinson’s disease and BMS‑986446 for Alzheimer’s disease at the AD/PD 2026 conference in Copenhagen. The PASADENA and PADOVA extensions suggest a two‑year disease‑progression delay and sustained biomarker effects, supporting the...
Light-Based Technique Creates Artificial Structures that Mimic the Scaffolding of Cells
Researchers at RIKEN have introduced a laser‑based optogenetic system that prints three‑dimensional actin networks directly onto lipid bilayers, effectively acting as a 3‑D printer for cytoskeletal scaffolds. By adjusting light intensity, pulse length, and pattern, they can independently control network...
Blood Test Predicts Long-Term Cognitive Function After Cardiac Arrest
A study presented at the ESC Acute Cardiovascular Care 2026 congress found that neurofilament light chain (NfL) measured 48 hours after out‑of‑hospital cardiac arrest reliably predicts long‑term cognitive function. Compared with the traditional biomarker neuron‑specific enolase (NSE), NfL showed a strong...
Metformin vs Dapagliflozin: Heart Protection in Diabetic Rats
Researchers compared metformin and dapagliflozin in diabetic rats subjected to myocardial infarction, finding dapagliflozin delivered stronger cardio‑protective effects. The SGLT2 inhibitor markedly reduced oxidative stress, inflammatory cytokines, and infarct size, while also improving calcium handling and contractile efficiency. Metformin showed...
Juicier Steaks Soon? The UK Approves Testing of Gene-Edited Cow Feed
British regulators have approved the first gene‑edited crop for animal feed, allowing Golden Promise barley with increased fat content to be tested on cattle. The modified barley is designed to accelerate weight gain, boost milk production and cut methane emissions...
How DICER Cuts microRNAs with Single-Nucleotide Precision
HKUST researchers have uncovered how human DICER achieves single‑nucleotide precision when cleaving microRNA precursors. Using high‑resolution cryo‑EM, they visualized DICER’s interaction with RNA and identified two distinct 5′‑end binding pockets—one favoring uridine and a newly discovered pocket favoring guanosine. The...
Noteworthy Studies on JAK Inhibitors, Skin-Gut Relationship in Alopecia Areata: Maria Hordinsky, MD
Maria Hordinsky, MD highlighted the rapid evolution of alopecia areata therapy, noting three FDA‑approved Janus kinase (JAK) inhibitors launched in the last five years. She discussed the efficacy of agents such as dupilumab and baricitinib, while emphasizing emerging research on...
Glenmark Launches GLIPIQ for Type 2 Diabetes in India
Glenmark Pharmaceuticals has launched GLIPIQ, a semaglutide‑based GLP‑1 therapy, in India following CDSCO approval after a local Phase III study. The product is offered in both vial‑with dose‑specific syringes and pre‑filled pen formats, covering 2 mg, 4 mg and 8 mg strengths. Pricing is...
Study Finds FGFR1 Boosts Cholesterol Uptake in Prostate Cancer Cells
Researchers at Texas A&M Health discovered that the fibroblast growth factor receptor 1 (FGFR1) drives cholesterol accumulation in prostate cancer cells by activating the sterol regulatory element‑binding protein 2 (SREBP2). This signaling cascade up‑regulates LDL‑receptor (LDLR) and cholesterol‑synthesis enzymes, boosting intracellular cholesterol...
Aelis Farma Announces the Successful Start of the Recruitment of the Phase 2B Clinical Trial with AEF0217 for the Treatment...
Aelis Farma announced that recruitment has begun for its Phase 2B trial of AEF0217, a first‑in‑class signalling‑specific CB1 receptor inhibitor, aimed at treating behavioral and cognitive impairments in Down syndrome. The study will enroll 188 participants aged 16‑32 across ten...
What Is Flumist, the New Flu Vaccine for Kids That's Sprayed in Their Noses?
Australia will introduce FluMist, a needle‑free nasal flu vaccine for children aged 2‑17, this winter. The live‑attenuated spray targets the upper respiratory tract and offers protection comparable to injectable shots, reducing flu cases by 40‑60%. It will be free for...
Comprehensive Single-Cell Transcriptomic Atlas of Microglia in Alzheimer’s Disease Mouse Models
A new study delivers a comprehensive single‑cell transcriptomic atlas of microglia from multiple Alzheimer’s disease mouse models. By profiling thousands of cells, researchers uncovered diverse microglial states, including disease‑associated subtypes linked to TREM2 signaling and amyloid pathology. The atlas integrates...
LINC01116 Binds CPS1 to Regulate Urea Cycle Function, Thereby Promoting Progression and Chemoresistance in Osteosarcoma
The study reveals that the long non‑coding RNA LINC01116 is markedly up‑regulated in metastatic osteosarcoma and directly binds the urea‑cycle enzyme CPS1. Disruption of the LINC01116‑CPS1 interaction impairs citrulline production, indicating a compromised urea cycle, and markedly suppresses tumor proliferation...
FDA Drug Safety Communication: Planned Return of CardioGen-82 to Market with New Boxed Warning
On February 15, 2012, the FDA announced that Bracco Diagnostics’ CardioGen‑82 generator will re-enter the U.S. market after a voluntary recall in July 2011. The agency approved revised labeling that introduces a Boxed Warning and new “Alert Limits” for strontium‑82...
FDA Drug Safety Communication: Safety Update on Progressive Multifocal Leukoencephalopathy (PML) Associated with Tysabri (Natalizumab)
The FDA has revised the Tysabri (natalizumab) label to detail progressive multifocal leukoencephalopathy (PML) risk based on infusion count and prior immunosuppressant exposure. Data show 102 PML cases among 82,732 treated patients, with incidence rising sharply after 24 infusions. A...
'Meaningful' FDA Clearance Opens New Osteoarthritis Treatment Pathway
The FDA has granted clearance for Siemens Healthineers’ Varian radiotherapy platforms—including TrueBeam, TrueBeam STx, VitalBeam and Edge—to treat medically refractory osteoarthritis in adults. Low‑dose radiation therapy offers a non‑invasive alternative to steroid injections, physical therapy, and ultimately joint replacement surgery...
